CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success?
Crossref DOI link: https://doi.org/10.1186/s13287-017-0511-8
Published Online: 2017-03-09
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gerace, Dario
Martiniello-Wilks, Rosetta
Nassif, Najah Therese
Lal, Sara
Steptoe, Raymond
Simpson, Ann Margaret
Funding for this research was provided by:
University of Technology Sydney